CD19 and metastatic malignant neoplasm in the lymph nodes: Interestingly, we found significantly increased CD19+ B cells in the P-PBMC in patients with lymph node metastasis compared to those with no lymph node metastasis (p < 0.01) (Figure 4d, CD19 panel).